Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
Sign Up to like & getrecommendations! Published in 2022 at "Lung cancer"
DOI: 10.1016/j.lungcan.2022.02.003
Abstract: INTRODUCTION Immune-mediated adverse events (imAEs), including all-cause immune-mediated pneumonitis, were reported in approximately 25% of patients in the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up to 12 months) in patients with unresectable, stage… read more here.
Keywords: durvalumab; imaes; pneumonitis; non pneumonitis ... See more keywords